BIO-Europe 2025: Anavo Therapeutics is focused on phosphatases - and is publicly talking about its two lead programs for the first time
Nov 3, 2025
11:11
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
CEO Birgit Zech and CSO Edward Holson discuss the unique beginning of the company (a powerpoint deck), and the difficulties in drugging phosphatases. Plus, the company is now disclosing two indications/targets in development.
BiotechTV - News